Paris—Global law firm Dentons advised three investment funds - Abenex, Ouest Croissance and Bpifrance – as shareholders, on the sale of Laboratoire Lescuyer to the Lorraine-based natural health group Laboratoires Lehning. With this transaction, Laboratoires Lehning continues the diversification of its group.  It also aims to accelerate the growth of the brands of both laboratories, by leveraging the synergies between their complementary product lines and distribution channels.

Founded by Jean-François Lescuyer in 1994, Laboratoire Lescuyer is one of the French leaders in health-promoting dietary supplements. Laboratoire Lescuyer’s products are formulated in-house, in La Rochelle, from high-quality natural active ingredients.

Specialized for nearly a century in homeopathic products sold in pharmacies, Laboratoires Lehning employs 370 employees and generates sales of €70 million.

Dentons' Corporate Life Sciences team in Paris advised Lescuyer’s shareholders on all aspects of the transaction.  Partner Anne-Laure Marcerou led the deal, with support from partner Olivia Gueguen and a team of associates comprised of Laura Godard, Marie Decrette and Guillaume Béraud.

Dentons also assisted Abenex during the leveraged buyout (LBO) of Laboratoire Lescuyer in 2016.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com